Can India, S Africa COVID IPR Waiver Request Gain Traction?
A proposal from India and South Africa to unlock patents on COVID-19 medicines and tools has put the spotlight back on intellectual property rights issues. Pharma may want to keep a close eye on progress, especially if momentum builds or issues are left open-ended.
You may also be interested in...
Gilead’s voluntary licensing of remdesivir to five companies while temporarily charging no royalty and allowing them pricing latitude for 127 developing countries not only expands market access but tilts the pricing debate in Gilead’s favor. It also brings significant potential add-on manufacturing capacity.
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.
Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.